DV
Dividend Vision

BBP — Virtus LifeSci Biotech Products ETF

Virtus LifeSci Biotech Products ETF (BBP)

BBP carries a 0.34% expense ratio. Total return is 294.8% over the past 11.7 years, 73.5 points behind SPY at 368.3%. Its deepest 1-year drawdown was 9.4%.

Virtus LifeSci Biotech Products ETF tracks an index of U.S.-listed biotechnology companies that have at least one FDA-approved drug therapy, holding a concentrated portfolio of approved biotech stocks. The fund does not currently distribute to shareholders, and carries an expense ratio of 0.34%. It appeals to investors seeking exposure to the biotechnology sector who prioritize companies with validated drug pipelines over earlier-stage development.

BBP key facts

Issuer
Virtus Investment Partners
Asset type
ETF
Asset class
Equity
Inception date
12/16/2014
Expense ratio
0.34%
Last close
$101.31
AUM
$91,496,801
Average volume
11200.0
Ex-dividend date
12/20/2017
Payment date
12/27/2017
Beta
0.79